A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as
adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery
without neoadjuvant therapy. The main question it aims to answer is:
• Efficacy of sintilimab as adjuvant therapy Participants will receive sintilimab 200 mg once
on day 1, every 21 days(Q3W).